For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Gynecologic Cancer

Gynecologic Cancer

AFT-50

Official Title: A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Study Purpose: To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.
Status: Pending
Gynecologic Cancer

GOG-0263

Official Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Study Purpose: To determine if adding chemotherapy to radiation therapy (CRT) can prevent or lengthen the time to recurrence when compared to radiation therapy (RT) alone.
Status: Recruiting
Gynecologic Cancer

GOG-3035/OncoQuest QPT-ORE-005/FLORA-5

Official Title: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel – Carboplatin - Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Study Purpose: To see how safe and effective four doses of the experimental drug oregovomab is given at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.
Status: Pending
Gynecologic Cancer

Gradalis CL-PTL-135

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research
Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.
Status: Recruiting
Gynecologic Cancer

GY023

Official Title: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Study Purpose: To compare the usual treatment alone to using combinations of durvalumab (MEDI4736), olaparib, and cediranib to increase the duration of time that your cancer does not progress.
Status: Recruiting
Gynecologic Cancer

InterVenn OVACA-001

Official Title: Clinical Validation of the InterVenn Ovarian Cancer Liquid Biopsy: VOCAL Study
Study Purpose: To evaluate the clinical performance for the InterVenn Ovarian Cancer Liquid Biopsy by collecting and storing blood samples and characterizing protein biomarkers in the blood of cancer vs. non-cancer patients.
Status: Recruiting
Gynecologic Cancer

LAE002INT2001/GOG-3044

Official Title: An Open-Label Randomized Active- Controlled Phase Ii Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer
Study Purpose: To evaluate the efficacy of afuresertib in combination with paclitaxel when compared to paclitaxel alone in patients with platinum-resistant ovarian cancer.
Status: Available
Gynecologic Cancer

MER-XMT-1536-1/GOG-3048

Official Title: A Phase 1B/2, First-In-Human, Dose Escalation And Expansion Study Of XMT-1536 In Patients With Solid Tumors Likely To Express NAPI2B
Study Purpose: The purpose of testing your tumor samples for levels of the NaPi2b protein or RNA is to evaluate whether this testing can be used as a tool to help determine if a patient’s cancer will respond to treatment for future patients prior to their dosing with XMT-1536.
Status: Recruiting
Gynecologic Cancer

NRG CC008

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.
Status: Recruiting
Gynecologic Cancer

NRG GY012

Official Title: Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.
Study Purpose: To compare the safety and effects of cediranib alone, combinations of olaparib with AZD5363 (capivasertib), or durvalumab (MEDI4736) or the combination of cediranib and durvalumab (MEDI4736).
Status: Recruiting